Overview

Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients

Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Prospective, open-labeled, multicenter cohort trial for validation of the role of levetiracetam as a sensitizer of temozolomide in the treatment of newly diagnosed glioblastoma patients.
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Etiracetam
Levetiracetam
Piracetam
Temozolomide